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Dear Sir, With the identification and a better understanding of the galectin family 1 , accumulating evidence supports a role for galectin-3 (Gal-3) in cell adhesion, cell growth, motility, invasion and the metastatic process 2 . In the November 2006 issue of Clinical Cancer Research the article by Prieto et al. 3 on immunodetection of Gal-3 in benign and malignant melanocytic cutaneous lesions underlines the presence of this protein in melanoma tissue. They found an overexpression in primary and metastatic melanoma lesions compared with nevi and suggested that Gal-3 could play a role in the acquisition of a malignant phenotype. Furthermore, the authors evoked a relationship between Gal-3 expression and prognosis; more precisely between a high cytoplasmic to nuclear expression ratio and poor prognosis.
We recently published a paper on Gal-3 in The Journal of International Medical Research 4 and, therefore, take this opportunity to make three comments.
(i) In order to explore the possible role of Gal-3 in cutaneous malignant melanoma (CMM), we recently initiated immunohistochemical studies. These have been now been published 5 and have demonstrated a higher level of expression of Gal-3 in pT1 primary melanoma lesions compared with benign nevi. The results of these investigations are consistent with the report of Prieto et al. 3 (ii) It should be noted that the heterogenous expression of Gal-3 in tumour tissue needs careful description, i.e. whether it is cellular/extracellular or nuclear/cytoplasmic in location, and results should be interpreted with caution. Indeed, in our studies, we observed wide variability in Gal-3 immunodetection within the same tumour as measured semi-quantitatively by immunochemistry. In our experience Gal-3 immunostaining is highly reproducible and, therefore, one can speculate that there is differential expression of Gal-3 by the melanoma cells, which should be investigated.
(iii) Since we had also shown a higher serum level of Gal-3 in advanced melanoma patients 6 
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patients and found that they had a higher Gal-3 serum level compared with AJCC stage 1 and 2 melanoma patients ( Fig. 1) and healthy volunteer controls. Moreover, high serum levels of Gal-3 significantly correlated with reduced patient survival (data not shown). All these data, therefore, indicate that Gal-3 shows promise as a diagnostic and/or has prognostic value in CMM. Nonetheless it will be useful to clarify the biological role of this protein in the malignant progression of CMM.
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